Ivabradine HCl
≥98%
- Product Code: 73671
CAS:
148849-67-6
| Molecular Weight: | 505.05 g./mol | Molecular Formula: | C₂₇H₃₆N₂O₅HCl |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD00929899 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2~8℃, dry, sealed |
Product Description:
Ivabradine HCl is primarily used in the treatment of chronic heart failure and stable angina pectoris. It works by selectively inhibiting the If current in the sinoatrial node, which helps to lower the heart rate without affecting myocardial contractility or blood pressure. This makes it particularly beneficial for patients who cannot tolerate beta-blockers or for whom beta-blockers are contraindicated. By reducing the heart rate, it decreases the oxygen demand of the heart, thereby alleviating symptoms of angina and improving exercise capacity. In heart failure patients, it has been shown to reduce the risk of hospitalization due to worsening heart failure. It is often prescribed as part of a comprehensive treatment plan that includes lifestyle changes and other medications.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | White to Almost white powder or crystal |
| PURITY | 97.5-100 |
| Infrared spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.250 | 10-20 days | $90.17 |
+
-
|
| 1.000 | 10-20 days | $286.48 |
+
-
|
Ivabradine HCl
Ivabradine HCl is primarily used in the treatment of chronic heart failure and stable angina pectoris. It works by selectively inhibiting the If current in the sinoatrial node, which helps to lower the heart rate without affecting myocardial contractility or blood pressure. This makes it particularly beneficial for patients who cannot tolerate beta-blockers or for whom beta-blockers are contraindicated. By reducing the heart rate, it decreases the oxygen demand of the heart, thereby alleviating symptoms of angina and improving exercise capacity. In heart failure patients, it has been shown to reduce the risk of hospitalization due to worsening heart failure. It is often prescribed as part of a comprehensive treatment plan that includes lifestyle changes and other medications.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :